Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An intergroup rhabdomyosarcoma study

A. S. Pappo, E. Lyden, J. Breneman, E. Wiener, L. Teot, J. Meza, W. Crist, T. Vietti

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Purpose: To investigate the antitumor activity and toxicity of topotecan, used alone and in combination with conventional therapy, in patients with metastatic rhabdomyosarcoma (RMS). Patients and Methods: Forty-eight patients younger than 21 years of age with newly diagnosed metastatic RMS received 2.0 to 2.4 mg/m2 of topotecan intravenously daily for 5 days every 21 days before standard therapy. Two courses were given in the absence of progressive disease or excessive toxicity and response was assessed. Patients with at least a partial response (PR) to topotecan proceeded to therapy with alternating courses of vincristine 1.5 mg/m2, dactinomycin 1.5 mg/m2, and cyclophosphamide 2.2 g/m2 (VAC) and vincristine 1.5 mg/m2, topotecan 0.75 mg/m2 daily × 5, and cyclophosphamide 250 mg/m2 daily × 5. Patients who did not respond to topotecan received continuation therapy with VAC alone. Results: The overall response rate to topotecan was 46% (complete response, 4%; partial response 42%). Unexpectedly, patients with alveolar RMS had a higher rate of response (65%) than those with embryonal RMS (28%; P = .08). The most common grade 3 or 4 toxicities were neutropenia (67%), anemia (33%), thrombocytopenia (25%), and infection (21%). Two-year failure-free survival and survival estimates were 24% and 46%, respectively. Response to window therapy did not correlate with survival. Conclusion: The high response rate and acceptable toxicity profile of topotecan in children with advanced RMS support further evaluation of this agent in phase III trials. The superior responses in alveolar RMS are of interest.

Original languageEnglish (US)
Pages (from-to)213-219
Number of pages7
JournalJournal of Clinical Oncology
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2001

Fingerprint

Topotecan
Rhabdomyosarcoma
Alveolar Rhabdomyosarcoma
Vincristine
Cyclophosphamide
Survival
Embryonal Rhabdomyosarcoma
Therapeutics
Dactinomycin
Neutropenia
Thrombocytopenia
Anemia
Infection

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma : An intergroup rhabdomyosarcoma study. / Pappo, A. S.; Lyden, E.; Breneman, J.; Wiener, E.; Teot, L.; Meza, J.; Crist, W.; Vietti, T.

In: Journal of Clinical Oncology, Vol. 19, No. 1, 01.01.2001, p. 213-219.

Research output: Contribution to journalArticle

Pappo, A. S. ; Lyden, E. ; Breneman, J. ; Wiener, E. ; Teot, L. ; Meza, J. ; Crist, W. ; Vietti, T. / Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma : An intergroup rhabdomyosarcoma study. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 1. pp. 213-219.
@article{4c598d779fb241ae8548bcb51e8f733e,
title = "Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An intergroup rhabdomyosarcoma study",
abstract = "Purpose: To investigate the antitumor activity and toxicity of topotecan, used alone and in combination with conventional therapy, in patients with metastatic rhabdomyosarcoma (RMS). Patients and Methods: Forty-eight patients younger than 21 years of age with newly diagnosed metastatic RMS received 2.0 to 2.4 mg/m2 of topotecan intravenously daily for 5 days every 21 days before standard therapy. Two courses were given in the absence of progressive disease or excessive toxicity and response was assessed. Patients with at least a partial response (PR) to topotecan proceeded to therapy with alternating courses of vincristine 1.5 mg/m2, dactinomycin 1.5 mg/m2, and cyclophosphamide 2.2 g/m2 (VAC) and vincristine 1.5 mg/m2, topotecan 0.75 mg/m2 daily × 5, and cyclophosphamide 250 mg/m2 daily × 5. Patients who did not respond to topotecan received continuation therapy with VAC alone. Results: The overall response rate to topotecan was 46{\%} (complete response, 4{\%}; partial response 42{\%}). Unexpectedly, patients with alveolar RMS had a higher rate of response (65{\%}) than those with embryonal RMS (28{\%}; P = .08). The most common grade 3 or 4 toxicities were neutropenia (67{\%}), anemia (33{\%}), thrombocytopenia (25{\%}), and infection (21{\%}). Two-year failure-free survival and survival estimates were 24{\%} and 46{\%}, respectively. Response to window therapy did not correlate with survival. Conclusion: The high response rate and acceptable toxicity profile of topotecan in children with advanced RMS support further evaluation of this agent in phase III trials. The superior responses in alveolar RMS are of interest.",
author = "Pappo, {A. S.} and E. Lyden and J. Breneman and E. Wiener and L. Teot and J. Meza and W. Crist and T. Vietti",
year = "2001",
month = "1",
day = "1",
doi = "10.1200/JCO.2001.19.1.213",
language = "English (US)",
volume = "19",
pages = "213--219",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma

T2 - An intergroup rhabdomyosarcoma study

AU - Pappo, A. S.

AU - Lyden, E.

AU - Breneman, J.

AU - Wiener, E.

AU - Teot, L.

AU - Meza, J.

AU - Crist, W.

AU - Vietti, T.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Purpose: To investigate the antitumor activity and toxicity of topotecan, used alone and in combination with conventional therapy, in patients with metastatic rhabdomyosarcoma (RMS). Patients and Methods: Forty-eight patients younger than 21 years of age with newly diagnosed metastatic RMS received 2.0 to 2.4 mg/m2 of topotecan intravenously daily for 5 days every 21 days before standard therapy. Two courses were given in the absence of progressive disease or excessive toxicity and response was assessed. Patients with at least a partial response (PR) to topotecan proceeded to therapy with alternating courses of vincristine 1.5 mg/m2, dactinomycin 1.5 mg/m2, and cyclophosphamide 2.2 g/m2 (VAC) and vincristine 1.5 mg/m2, topotecan 0.75 mg/m2 daily × 5, and cyclophosphamide 250 mg/m2 daily × 5. Patients who did not respond to topotecan received continuation therapy with VAC alone. Results: The overall response rate to topotecan was 46% (complete response, 4%; partial response 42%). Unexpectedly, patients with alveolar RMS had a higher rate of response (65%) than those with embryonal RMS (28%; P = .08). The most common grade 3 or 4 toxicities were neutropenia (67%), anemia (33%), thrombocytopenia (25%), and infection (21%). Two-year failure-free survival and survival estimates were 24% and 46%, respectively. Response to window therapy did not correlate with survival. Conclusion: The high response rate and acceptable toxicity profile of topotecan in children with advanced RMS support further evaluation of this agent in phase III trials. The superior responses in alveolar RMS are of interest.

AB - Purpose: To investigate the antitumor activity and toxicity of topotecan, used alone and in combination with conventional therapy, in patients with metastatic rhabdomyosarcoma (RMS). Patients and Methods: Forty-eight patients younger than 21 years of age with newly diagnosed metastatic RMS received 2.0 to 2.4 mg/m2 of topotecan intravenously daily for 5 days every 21 days before standard therapy. Two courses were given in the absence of progressive disease or excessive toxicity and response was assessed. Patients with at least a partial response (PR) to topotecan proceeded to therapy with alternating courses of vincristine 1.5 mg/m2, dactinomycin 1.5 mg/m2, and cyclophosphamide 2.2 g/m2 (VAC) and vincristine 1.5 mg/m2, topotecan 0.75 mg/m2 daily × 5, and cyclophosphamide 250 mg/m2 daily × 5. Patients who did not respond to topotecan received continuation therapy with VAC alone. Results: The overall response rate to topotecan was 46% (complete response, 4%; partial response 42%). Unexpectedly, patients with alveolar RMS had a higher rate of response (65%) than those with embryonal RMS (28%; P = .08). The most common grade 3 or 4 toxicities were neutropenia (67%), anemia (33%), thrombocytopenia (25%), and infection (21%). Two-year failure-free survival and survival estimates were 24% and 46%, respectively. Response to window therapy did not correlate with survival. Conclusion: The high response rate and acceptable toxicity profile of topotecan in children with advanced RMS support further evaluation of this agent in phase III trials. The superior responses in alveolar RMS are of interest.

UR - http://www.scopus.com/inward/record.url?scp=0035155499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035155499&partnerID=8YFLogxK

U2 - 10.1200/JCO.2001.19.1.213

DO - 10.1200/JCO.2001.19.1.213

M3 - Article

C2 - 11134215

AN - SCOPUS:0035155499

VL - 19

SP - 213

EP - 219

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -